Sign In
Buy CERT
$8.10
+0.320 (+4.11%)
At Close: Jul 31, 2026
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions
04:15pm, Wednesday, 05'th Mar 2025
RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D.
Certara, Inc. (CERT) Q4 2024 Earnings Call Transcript
08:03pm, Wednesday, 26'th Feb 2025
Certara, Inc. (NASDAQ:CERT ) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executi
Certara, Inc. (CERT) Surpasses Q4 Earnings and Revenue Estimates
07:45pm, Wednesday, 26'th Feb 2025
Certara, Inc. (CERT) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.09 per share a year ago.
Certara Reports Fourth Quarter 2024 Financial Results
04:15pm, Wednesday, 26'th Feb 2025
RADNOR, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the fourth quarter and full ye
RADNOR, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth q
Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results
07:55am, Wednesday, 15'th Jan 2025
Full-Year 2024 Revenue of $384.4 million, Bookings of $445.3 million Confirms Adjusted EBITDA within Guidance Range of $120 million to $124 million
Final Trade: CERT, XLE, DAL, OKTA
07:14pm, Friday, 10'th Jan 2025
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
04:15pm, Thursday, 02'nd Jan 2025
RADNOR, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the 43rd An
Cerrado Gold Provides an Update on its Mont Sorcier High Purity 67%+ Iron Grade Project in Quebec
06:00am, Wednesday, 04'th Dec 2024
Detailed Metallurgical test work is ongoing and reaffirms production of DRI grade, 67%+ or better iron concentrate with combined Silica and Alumina below 2.5% Work Programs initiated and DRA Global ap
Certara Showcases 2024 Research Wins With Over 100 Papers Published
04:15pm, Monday, 02'nd Dec 2024
The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researc
Certara, Inc. (CERT) Q3 2024 Earnings Conference Call Transcript
09:09pm, Wednesday, 06'th Nov 2024
Certara, Inc. (CERT) Q3 2024 Earnings Conference Call Transcript
Certara, Inc. (CERT) Q3 Earnings Surpass Estimates
08:05pm, Wednesday, 06'th Nov 2024
Certara, Inc. (CERT) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.11 per share a year ago.
Certara Reports Third Quarter 2024 Financial Results
04:15pm, Wednesday, 06'th Nov 2024
RADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal ye
Certara to Participate in the Stephens Annual Investment Conference
04:15pm, Monday, 28'th Oct 2024
RADNOR, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the Stephen
Certara Appoints John Reynders as New Independent Board Member
04:15pm, Wednesday, 16'th Oct 2024
RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of
